Index fell 7.66% in February to be the second-worst performing sector for the month as the local bourse felt the pressure of ...

Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

The Middle East healthcare sector is undergoing rapid expansion presenting opportunities for ASX-listed companies.

Dr Nina Webster is the CEO and managing director of Dimerix (ASX:DXB), which in mid-CY25 is due to report the second interim results of its ACTION3 global phase III trial of lead drug DMX-200 to treat ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.

The stock traded at 58 cents this morning, so is not too far off the strike price for the ‘loyalties’. At Stockhead, we tell it is as it is. While Paradigm, EBR, Dimerix, Aroa and Blinklab are ...

KP is Chief Scientific Advisor to Dimerix, of which he has a shareholding. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships ...